Drug intelligence / Profile preview

3C Plus

Development stage: Unknown
Lead developer: Solis Pharms
Modality: Small Molecules
Administration: Oral

Overview

3C Plus is an oral combination nutraceutical and mineral-vitamin formulation developed by Solis Pharms. It is designed to support bone health and address nutritional deficiencies. The formulation contains two forms of calcium (aspartate and orotate) for optimal absorption, calcitriol (active Vitamin D3) to facilitate calcium transport, magnesium hydroxide and zinc for bone matrix mineralization, and B-vitamins (hydroxocobalamin and folic acid) to manage homocysteine levels and support cellular metabolism. It is typically indicated for conditions like osteoporosis, osteopenia, and general calcium/vitamin deficiency.

Brand names: 3C Plus
Other names: Calcium Aspartate + Calcium Orotate + Calcitriol + Zinc + Magnesium hydroxide + Hydroxocobalamin + Folic Acid

Targets

DHFR (Dihydrofolate reductase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on 3C Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3C Plus.

Explore the full profile